Doctoral student earns NIH award to investigate endometrial cancer vulnerabilities Today@Wayne
Doctoral student earns NIH award to investigate endometrial cancer vulnerabilities today.wayne.edu
Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …
To compare the clinical effectiveness of combined oral contraceptive pills (levonorgestrel-containing COC) and dienogest in the management of endometriosis-associated chronic pelvic pain and related symptoms.
Oral GnRH Antagonists Expand Choice, Not Cure streamlinefeed.co.ke
Endometriosis has limited treatment options, prompting the search for data-driven therapeutics. We previously used a transcriptomics-based computational drug repositioning pipeline and identified several drug candidates. Fenoprofen, our top in silico …
This paper critically evaluates Sekiguchi et al.'s study of vaginal progesterone dose, serum progesterone thresholds, and reproductive outcomes in hormone replacement therapy frozen embryo transfer (HRT-FET) cycles. The study conflates …
Background: This review aims to systematically summarize the lineage origins, subtype classification, and functional dynamics of endometrial macrophages, clarify their mechanisms of action in normal reproductive physiology (menstrual cycle, pregnancy) …
In women with uterine adenomyosis, bleeding and pain can have a major impact on quality of life. There is clearly widespread demand for effective long-term medical therapies. The objective of …
Male fertility is declining, and synthetic chemicals are a major candidate for causing it. This study investigated the effect of oral consumption of perfluorooctanoic acid on sperm quality and in …